An international dosimetry exchange for boron neutron capture therapy. Part II: Computational dosimetry normalizations

K.J. Riley, P.J. Binns, O.K. Harling, J.R. Albritton, W.S. Kiger III, A. Rezaei, K. Sköld, T. Seppalä, S. Savolainen, Iiro Auterinen, M. Marek, L. Viererbl, V.A. Nievaart, R.L. Moss

Research output: Contribution to journalArticleScientificpeer-review

11 Citations (Scopus)

Abstract

The meaningful sharing and combining of clinical results from different centers in the world performing boron neutron capture therapy (BNCT) requires improved precision in dose specification between programs. To this end absorbed dose normalizations were performed for the European clinical centers at the Joint Research Centre of the European Commission, Petten (The Netherlands), Nuclear Research Institute, Rez (Czech Republic), VTT, Espoo (Finland), and Studsvik, Nyköping (Sweden). Each European group prepared a treatment plan calculation that was benchmarked against Massachusetts Institute of Technology (MIT) dosimetry performed in a large, water‐filled phantom to uniformly evaluate dose specifications with an estimated precision +-2%-3%. These normalizations were compared with those derived from an earlier exchange between Brookhaven National Laboratory (BNL) and MIT in the USA. Neglecting the uncertainties related to biological weighting factors, large variations between calculated and measured dose are apparent that depend upon the 10 Β uptake in tissue. Assuming a boron concentration of 15 μ gg -1 in normal tissue, differences in the evaluated maximum dose to brain for the same nominal specification of 10 Gy(w) at the different facilities range between 7.6 and 13.2 Gy(w) in the trials using boronophenylalanine (BPA) as the boron delivery compound and between 8.9 and 11.1 Gy(w) in the two boron sulfhydryl (BSH) studies. Most notably, the value for the same specified dose of 10 Gy(w) determined at the different participating centers using BPA is significantly higher than at BNL by 32% (MIT), 43% (VTT), 49% (JRC), and 74% (Studsvik). Conversion of dose specification is now possible between all active participants and should be incorporated into future multi‐center patient analyses.

Original languageEnglish
Pages (from-to)5419-5425
Number of pages7
JournalMedical Physics
Volume35
Issue number12
DOIs
Publication statusPublished - 2008
MoE publication typeA1 Journal article-refereed

Fingerprint

Boron Neutron Capture Therapy
Boron
Technology
Boron Compounds
Czech Republic
Biological Factors
Finland
Sweden
Netherlands
Uncertainty
Brain
Research

Keywords

  • Boron neutron capture therapy
  • BNCT
  • thermal neutrons
  • dosimetry intercomparison
  • clinical trials

Cite this

Riley, K. J., Binns, P. J., Harling, O. K., Albritton, J. R., Kiger III, W. S., Rezaei, A., ... Moss, R. L. (2008). An international dosimetry exchange for boron neutron capture therapy. Part II: Computational dosimetry normalizations. Medical Physics, 35(12), 5419-5425. https://doi.org/10.1118/1.3005480
Riley, K.J. ; Binns, P.J. ; Harling, O.K. ; Albritton, J.R. ; Kiger III, W.S. ; Rezaei, A. ; Sköld, K. ; Seppalä, T. ; Savolainen, S. ; Auterinen, Iiro ; Marek, M. ; Viererbl, L. ; Nievaart, V.A. ; Moss, R.L. / An international dosimetry exchange for boron neutron capture therapy. Part II : Computational dosimetry normalizations. In: Medical Physics. 2008 ; Vol. 35, No. 12. pp. 5419-5425.
@article{b2d2e24663a54d348270a1a66f10c407,
title = "An international dosimetry exchange for boron neutron capture therapy. Part II: Computational dosimetry normalizations",
abstract = "The meaningful sharing and combining of clinical results from different centers in the world performing boron neutron capture therapy (BNCT) requires improved precision in dose specification between programs. To this end absorbed dose normalizations were performed for the European clinical centers at the Joint Research Centre of the European Commission, Petten (The Netherlands), Nuclear Research Institute, Rez (Czech Republic), VTT, Espoo (Finland), and Studsvik, Nyk{\"o}ping (Sweden). Each European group prepared a treatment plan calculation that was benchmarked against Massachusetts Institute of Technology (MIT) dosimetry performed in a large, water‐filled phantom to uniformly evaluate dose specifications with an estimated precision +-2{\%}-3{\%}. These normalizations were compared with those derived from an earlier exchange between Brookhaven National Laboratory (BNL) and MIT in the USA. Neglecting the uncertainties related to biological weighting factors, large variations between calculated and measured dose are apparent that depend upon the 10 Β uptake in tissue. Assuming a boron concentration of 15 μ gg -1 in normal tissue, differences in the evaluated maximum dose to brain for the same nominal specification of 10 Gy(w) at the different facilities range between 7.6 and 13.2 Gy(w) in the trials using boronophenylalanine (BPA) as the boron delivery compound and between 8.9 and 11.1 Gy(w) in the two boron sulfhydryl (BSH) studies. Most notably, the value for the same specified dose of 10 Gy(w) determined at the different participating centers using BPA is significantly higher than at BNL by 32{\%} (MIT), 43{\%} (VTT), 49{\%} (JRC), and 74{\%} (Studsvik). Conversion of dose specification is now possible between all active participants and should be incorporated into future multi‐center patient analyses.",
keywords = "Boron neutron capture therapy, BNCT, thermal neutrons, dosimetry intercomparison, clinical trials",
author = "K.J. Riley and P.J. Binns and O.K. Harling and J.R. Albritton and {Kiger III}, W.S. and A. Rezaei and K. Sk{\"o}ld and T. Seppal{\"a} and S. Savolainen and Iiro Auterinen and M. Marek and L. Viererbl and V.A. Nievaart and R.L. Moss",
year = "2008",
doi = "10.1118/1.3005480",
language = "English",
volume = "35",
pages = "5419--5425",
journal = "Medical Physics",
issn = "0094-2405",
number = "12",

}

Riley, KJ, Binns, PJ, Harling, OK, Albritton, JR, Kiger III, WS, Rezaei, A, Sköld, K, Seppalä, T, Savolainen, S, Auterinen, I, Marek, M, Viererbl, L, Nievaart, VA & Moss, RL 2008, 'An international dosimetry exchange for boron neutron capture therapy. Part II: Computational dosimetry normalizations', Medical Physics, vol. 35, no. 12, pp. 5419-5425. https://doi.org/10.1118/1.3005480

An international dosimetry exchange for boron neutron capture therapy. Part II : Computational dosimetry normalizations. / Riley, K.J.; Binns, P.J.; Harling, O.K.; Albritton, J.R.; Kiger III, W.S.; Rezaei, A.; Sköld, K.; Seppalä, T.; Savolainen, S.; Auterinen, Iiro; Marek, M.; Viererbl, L.; Nievaart, V.A.; Moss, R.L.

In: Medical Physics, Vol. 35, No. 12, 2008, p. 5419-5425.

Research output: Contribution to journalArticleScientificpeer-review

TY - JOUR

T1 - An international dosimetry exchange for boron neutron capture therapy. Part II

T2 - Computational dosimetry normalizations

AU - Riley, K.J.

AU - Binns, P.J.

AU - Harling, O.K.

AU - Albritton, J.R.

AU - Kiger III, W.S.

AU - Rezaei, A.

AU - Sköld, K.

AU - Seppalä, T.

AU - Savolainen, S.

AU - Auterinen, Iiro

AU - Marek, M.

AU - Viererbl, L.

AU - Nievaart, V.A.

AU - Moss, R.L.

PY - 2008

Y1 - 2008

N2 - The meaningful sharing and combining of clinical results from different centers in the world performing boron neutron capture therapy (BNCT) requires improved precision in dose specification between programs. To this end absorbed dose normalizations were performed for the European clinical centers at the Joint Research Centre of the European Commission, Petten (The Netherlands), Nuclear Research Institute, Rez (Czech Republic), VTT, Espoo (Finland), and Studsvik, Nyköping (Sweden). Each European group prepared a treatment plan calculation that was benchmarked against Massachusetts Institute of Technology (MIT) dosimetry performed in a large, water‐filled phantom to uniformly evaluate dose specifications with an estimated precision +-2%-3%. These normalizations were compared with those derived from an earlier exchange between Brookhaven National Laboratory (BNL) and MIT in the USA. Neglecting the uncertainties related to biological weighting factors, large variations between calculated and measured dose are apparent that depend upon the 10 Β uptake in tissue. Assuming a boron concentration of 15 μ gg -1 in normal tissue, differences in the evaluated maximum dose to brain for the same nominal specification of 10 Gy(w) at the different facilities range between 7.6 and 13.2 Gy(w) in the trials using boronophenylalanine (BPA) as the boron delivery compound and between 8.9 and 11.1 Gy(w) in the two boron sulfhydryl (BSH) studies. Most notably, the value for the same specified dose of 10 Gy(w) determined at the different participating centers using BPA is significantly higher than at BNL by 32% (MIT), 43% (VTT), 49% (JRC), and 74% (Studsvik). Conversion of dose specification is now possible between all active participants and should be incorporated into future multi‐center patient analyses.

AB - The meaningful sharing and combining of clinical results from different centers in the world performing boron neutron capture therapy (BNCT) requires improved precision in dose specification between programs. To this end absorbed dose normalizations were performed for the European clinical centers at the Joint Research Centre of the European Commission, Petten (The Netherlands), Nuclear Research Institute, Rez (Czech Republic), VTT, Espoo (Finland), and Studsvik, Nyköping (Sweden). Each European group prepared a treatment plan calculation that was benchmarked against Massachusetts Institute of Technology (MIT) dosimetry performed in a large, water‐filled phantom to uniformly evaluate dose specifications with an estimated precision +-2%-3%. These normalizations were compared with those derived from an earlier exchange between Brookhaven National Laboratory (BNL) and MIT in the USA. Neglecting the uncertainties related to biological weighting factors, large variations between calculated and measured dose are apparent that depend upon the 10 Β uptake in tissue. Assuming a boron concentration of 15 μ gg -1 in normal tissue, differences in the evaluated maximum dose to brain for the same nominal specification of 10 Gy(w) at the different facilities range between 7.6 and 13.2 Gy(w) in the trials using boronophenylalanine (BPA) as the boron delivery compound and between 8.9 and 11.1 Gy(w) in the two boron sulfhydryl (BSH) studies. Most notably, the value for the same specified dose of 10 Gy(w) determined at the different participating centers using BPA is significantly higher than at BNL by 32% (MIT), 43% (VTT), 49% (JRC), and 74% (Studsvik). Conversion of dose specification is now possible between all active participants and should be incorporated into future multi‐center patient analyses.

KW - Boron neutron capture therapy

KW - BNCT

KW - thermal neutrons

KW - dosimetry intercomparison

KW - clinical trials

U2 - 10.1118/1.3005480

DO - 10.1118/1.3005480

M3 - Article

VL - 35

SP - 5419

EP - 5425

JO - Medical Physics

JF - Medical Physics

SN - 0094-2405

IS - 12

ER -